Santhera Pharmaceuticals

Map of Canada
#Duchenne muscular dystrophy #Health Canada #Paediatrics #Santhera Pharmaceuticals

First Duchenne muscular dystrophy treatment approved in Canada

The first treatment for Duchenne muscular dystrophy (DMD) has been approved in Canada. Santhera Pharmaceuticals announced that Health Canada approved the company’s Agamree (vamorolone) therapy for DMD in patients four years and older. DMD is a rare inherited X-chromosome-linked disease primarily affecting males. It is characterised by inflammation which is… Read More

#News #Regulatory

Heart
#Cardiovascular disease #Corticosteroids #Duchenne muscular dystrophy #Paediatrics #Santhera Pharmaceuticals

Vamorolone demonstrates unique action as a mineralocorticoid RA

Santhera Pharmaceuticals has announced positive results from the LIONHEART study, confirming vamorolone’s action as a mineralocorticoid receptor antagonist, which the company says sets it apart from other corticosteroids. The LIONHEART study in 30 healthy adult male subjects demonstrated a statistically significant increase in the urinary sodium/potassium… Read More

#News